scispace - formally typeset
Open AccessJournal ArticleDOI

Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Systematic Review of the Literature and Challenges.

TLDR
A systematic review of the literature reporting cases of HIV and SARS-CoV-2 coinfection, and examine trends of clinical outcomes among coinfected patients is presented in this article.
Abstract
The concurrence of infection with human immunodeficiency virus (HIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), presents an intriguing problem with many uncertainties underlying their pathogenesis. Despite over 96.2 million cases of COVID-19 worldwide as of January 22, 2021, reports of patients coinfected with HIV and SARS-CoV-2 are scarce. It remains unknown whether HIV patients are at a greater risk of infection from SARS-CoV-2, despite their immunocompromised status. We present a systematic review of the literature reporting cases of HIV and SARS-CoV-2 coinfection, and examine trends of clinical outcomes among coinfected patients. We systematically compiled 63 reports of HIV-1 and SARS-CoV-2 coinfection, published as of January 22, 2021. These studies were retrieved through targeted search terms applied to PubMed/Medline and manual search. Despite scattered evidence, reports indicate a favorable prognosis for HIV patients with strict adherence to combined antiretroviral therapy (cART). However, the presence of comorbidities was associated with a poorer prognosis in HIV/SARS-CoV-2 patients, despite cART and viral suppression. Studies were limited by geographic coverage, small sample size, lack of patient details, and short follow-up durations. Although some anti-HIV drugs have shown promising in vitro activity against SARS-CoV-2, there is no conclusive evidence of the clinical efficacy of any anti-HIV drug in the treatment of COVID-19. Further research is needed to explain the under-representation of severe COVID-19 cases among the HIV patient population and to explore the possible protective mechanisms of cART in this vulnerable population.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection

TL;DR: In this paper, the authors review the currently available evidence on tenofovir's efficacy against SARS-CoV-2 infection and conclude that it is not the only antiviral medication approved for COVID-19.
Journal ArticleDOI

HIV infection and risk of COVID-19 mortality: A meta-analysis.

TL;DR: Wang et al. as mentioned in this paper performed a meta-analysis to estimate the association of human immunodeficiency virus (HIV) infection and risk of coronavirus disease 2019 (COVID-19) mortality.
Journal ArticleDOI

Global and Regional Prevalence and Outcomes of COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis

TL;DR: Although there is a low prevalence of PLWH among CO VID-19 cases, HIV infection may increase the severity of COVID-19 in Africa and increase the risk of death globally.

HIV and COVID-19: review of clinical course and outcomes

TL;DR: In this article, the authors conducted a search of PubMed, Scopus, pre-print databases (medRxiv, bioRXiv), and references of publications found using key terms relevant to COVID-19 ('COVID-18' or 'SARS-CoV-2' OR 'coronavirus') and to HIV ('HIV' OR "Human Immunodeficiency Virus' OR ''AIDS' OR Acquired Immunoviciency Syndrome').
Journal ArticleDOI

Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review

TL;DR: In this paper , the authors synthesized available data on the immune response to COVID-19 and critically assessed mRNA CoV-19 vaccine immunogenicity in this vulnerable subpopulation.
References
More filters
Journal ArticleDOI

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Journal ArticleDOI

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.

TL;DR: The symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease are highlighted.